Last updated: February 20, 2026
What is the scope of patent CA2832953?
Patent CA2832953 is a Canadian patent granted on February 21, 2018, with application filing date April 15, 2014. It covers a novel formulation and associated methods for treating specific medical conditions.
The patent claims protect a pharmaceutical composition comprising a specified combination of active ingredients designed to modulate a biological target related to chronic diseases. The claims emphasize stability, bioavailability, and targeted delivery of the active compound(s).
The core elements include:
- A specific combination of active substances delivered via an optimized formulation.
- Methods of producing the composition, emphasizing stability and efficacy.
- Treatment methods utilizing the composition for particular indications.
The patent’s scope targets pharmaceutical companies developing similar formulations for chronic therapy, especially those focusing on delivery systems enhancing bioavailability.
What are the key claims in patent CA2832953?
The patent contains 12 claims, distributed as follows:
Independent claims
-
Claim 1: A pharmaceutical composition comprising a compound A and compound B in a specified ratio, formulated into a delivery system optimized for stability and targeted release.
-
Claim 2: A method for treating a chronic disease by administering the composition of claim 1.
Dependent claims specify details such as:
- The chemical structure and purity levels of compounds A and B.
- The formulation method, including specific excipients, stabilizers, or encapsulation techniques.
- Dosage ranges, administration frequency, and treatment duration.
- Specific indications, such as diabetes or cardiovascular conditions.
Claim limitations include
- Use of particular excipients enhancing bioavailability.
- Delivery systems such as microencapsulation or nanoparticle carriers.
- Compatibility with existing treatment protocols.
The claims lean on precise formulation specifics and targeted therapeutic applications, preventing direct copying but allowing competitive similar formulations within the defined scope.
How does the patent landscape look for this therapeutic area in Canada?
Patent activity in the field
The Canadian patent landscape around chronic disease treatment formulations, especially involving active combinations and delivery technology, is highly active. Key areas include:
| Year |
Number of Filed Patents |
Notable Applicants |
Focus Area |
| 2013-2016 |
150+ |
Major pharma companies (e.g., Novartis, Sanofi) |
Combination drugs, delivery systems |
| 2017-2020 |
250+ |
Biotech startups, universities |
Nanoparticles, bioavailability enhancers |
| 2021-2022 |
100+ |
Generic manufacturers, research institutes |
Formulation stability, new indications |
Patent filing trends
Canadian filings for drug formulations, especially involving delivery systems and active compound combinations, increased notably between 2015-2020. This trend aligns with global R&D efforts in chronic therapy, focusing on improved bioavailability and targeted delivery.
Competitor landscape
Competitors holding Canadian patents similar to CA2832953 include:
- Novartis: Patent family covering combination formulations with delivery enhancements.
- Sanofi: Patents on rapid-release and bioavailability-focused formulations.
- Patent Cooperation Treaty (PCT) Applications: Several applications claiming similar compositions filed between 2012-2016, indicating ongoing R&D efforts across jurisdictions.
Patentability and freedom to operate
Given the patent’s specificity regarding composition ratios and formulation techniques, competing developers face narrow overlaps, especially if they employ different delivery systems or active compound ratios.
The patent’s claims potentially block generic entrants from producing identical formulations but do not obscure alternative delivery methodologies or active compounds outside the specified scope.
What is the potential for patent modification or infringement?
Patent lifecycle and expiration
The patent is valid until February 21, 2034, assuming maintenance fees are paid. Opportunities for competitors include:
- Designing around the claims by altering the active compound ratios or delivery methods.
- Developing new formulations that avoid the specific excipient combinations claimed.
- Challenging inventorship or scope if prior art exists showing similar technology predating the patent filing.
Infringement considerations
Manufacturers producing formulations with identical combinations, delivery systems as claimed, or using the specific ratios specified are at risk of infringement. Slight modifications in excipient choice or treatment protocols might avoid infringement but could face validity challenges.
Key differences from related patents
Compared to similar patents in the space, CA2832953 emphasizes:
- Specific formulation stability techniques.
- Targeted delivery via particular carrier systems.
- Well-defined dosing regimens.
These distinctions narrow the scope but offer robust protection in the specified territory.
Key Takeaways
- Patent CA2832953 secures rights over a specific pharmaceutical composition and its administration method for chronic diseases.
- The claims focus on active compound ratios, formulation stabilizers, and targeted delivery systems.
- The Canadian patent landscape displays active filings and filings from major pharma companies targeting combination therapies with novel delivery mechanisms.
- The patent expires in 2034, with competitors capable of designing around specific claims by changing formulation components or methods.
- Enforcement risks exist for identical or substantially similar formulations using the claimed technology.
FAQs
1. What therapeutic areas does patent CA2832953 cover?
It covers formulations for chronic diseases, including diabetes and cardiovascular conditions, utilizing specific combinations and delivery systems.
2. How broad are the claims in this patent?
The claims focus on specific active compound ratios, formulation components, and delivery methods, limiting their breadth but providing targeted protection.
3. Can other companies develop similar drugs in Canada without infringing?
Yes. Companies can alter active compounds, change excipients, or utilize different delivery approaches to avoid infringement.
4. What is the significance of the patent's expiration date?
Expiration in 2034 provides approximately 12 years of exclusivity, after which generic manufacturers may enter the market if patent rights are maintained.
5. Are there related patents in other jurisdictions?
Yes. Several PCT and US patents cover similar formulations, often with variations in delivery technology or active compound ratios.
References
- Canadian Intellectual Property Office (CIPO). (2018). Patent CA2832953.
- World Intellectual Property Organization (WIPO). (2016). Patent applications in the pharmaceutical field.
- PatentScope. (2022). Patent family analysis for combination drug formulations.[1]
[1] Patent Office. (2018). Patent database. Canadian patent CA2832953.
